Demand for weight loss drugs targeting GLP-1 has exploded in recent years, leading to disruptions in supply chains. Here are ...

Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage ...

Structure Therapeutics Inc. (NASDAQ ... then the goal would be to combine them with GLP-1 agonist GSBR-1290 to treat patients with obesity. The third risk to consider would be in terms of ...

“We know that without a better cost management structure, most employers will be unable to cover GLP-1 benefits for weight loss, despite the extraordinary efficacy of the medications in reducing ...

SAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of ...

Shares of Viking Therapeutics (NASDAQ: VKTX) fell on Monday, Nov. 4, despite some encouraging new data. Over the weekend, the ...

Powerful weight-loss drugs like Wegovy and Zepbound have driven nearly $1 trillion in market-capitalization gains, with most ...

Tirzepatide acts on GLP-1 plus glucose-dependent insulinotropic ... Lilly, Novo Nordisk, and Structure Therapeutics.

Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ETCompany ParticipantsJustin Schreiber – Chairman and Chief ...

These medications have been associated with a 40 percent reduction in opioid overdose and 50 percent lower rate of alcohol intoxication.